GlassScriptPhysician profile
Joshua E Nnanji
NPI 1821291550
$4,625.43
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $1,178 · 2021: $1,494 · 2022: $1,000.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $703.97 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $538.78 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $528.19 | 2019-2022 | |
| Alkermes, INC. | $493.20 | 2019-2022 | |
| Lundbeck LLC | $448.59 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $406.86 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $385.17 | 2019-2022 | |
| Allergan, INC. | $345.53 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $329.07 | 2020-2022 | |
| Abbvie INC. | $187.73 | 2021-2022 | |
| Indivior INC. | $78.21 | 2022 | |
| Avanir Pharmaceuticals, INC. | $69.56 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.23 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.13 | 2019 | |
| Harmony Biosciences LLC | $15.83 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $14.42 | 2021 | |
| Shire North American Group INC | $12.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Nnanji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.